Company: GIFLF
Filing Date: 2025-05-12
Form Type: 6-K
Source: 0001104659-25-047168
Chunk: 10

Company: Grifols SA
Filing Date: 2025-05-12
Form: 6-K
Chunk 10
---
ifols’s Global Network Mitigates Uncertainty From Potential Tariffs Los Angeles Clayton, North Carolina (NC) Montreal New Cairo Parets (BCN) Dublin SRAAS Dreieich Donor centers Biopharma manufacturing Strategic partnerships End - to - end and fully integrated in the US 300+ donor centers, representing >70% of plasma collection capacity in the US 2 manufacturing plants, accounting for ~65% of global fractionation and purification capacity in our core products to serve US demand 01 Strong presence in Europe Almost 100 donor centers in Europe, being Europe’s largest privately owned plasma center fleet 3 production facilities: Spain, Germany & Ireland 02 Local partnerships China: strong ongoing alliance with SRAAS, a leading player in China Egypt & Canada: self - sufficiency models, with DCs and manufacturing plants built or in construction 03 Currently, our expectation is of no meaningful impact Business Performance Financials Final Remarks Annex

- 10 - Q1 2025 Results Invested in Vertically Integrated Value Chain in the U.S. and Europe, Complemented by Strategic Hubs and Partnerships ex - U.S. 2002 2003 2011 2016 2017 2018 2019 2020 2021 2022 First 43 DCS First DCS LA plant • Clayton plant • DCs Dublin plant PlasmaVita JV DCs (Germany) SRAAS (China) • JV Egypt • Canada DC (Hungary) Biotest acquisition 1 2 3 • Started plasma center infrastructure in 2002 , with additional acquisition & organic openings • Acquisition of manufacturing plants in LA and Clayton • US infrastructure has benefited from multi - billion investments and will remain very well invested going forward Set US Infrastructure • Increased manufacturing capacity in Parets’ plant (Barcelona, Spain) • Set up European plasma centers through joint ventures and center acquisitions • Consolidation through manufacturing plant in Ireland and acquisition of majority of shares of Biotest Strengthen infrastructure in Europe • Strategic alliance with SRAAS / Haier • Joint Venture with Egyptian government • Canada manufacturing plant & CBS partnership Pioneer in local partnerships Donor centers Biopharma manufacturing Strategic partnerships Business Performance Financials Final Remarks Annex

- 11 - Q1 2025 Results Clear Focus on Execution Rahul Srinivasan Chief Financial Officer (CFO)

- 12 - Q1 2025 Results Q1’2025: Ahead of Plan Business Performance Financials Final Remarks Annex Note: All figures are